SyMap Medical Ltd. Announces its Strategic Collaboration with Pythagoras Medical
SUZHOU, China, Dec. 29, 2021 /PRNewswire/ -- SyMap Medical Ltd (SyMap) announced its strategic collaboration with Pythagoras Medical. With this win-win collaboration, SyMap has full rights to utilize all assets of Pythagoras, including their Renal Nerve Mapping System (ConfidenHT™, CE Mark Approval,) patents, trademarks and expertise. This collaboration will further enhance...
Seegene Airlifts 1.7 million COVID-19 Tests to Israel Battling the Omicron Variant by a charter plane
On December 29, Seegene to deliver Allplex™ SARS-CoV-2 Master Assay that can preemptively detect the Omicron variant at the primary screening stage Earlier this month, the company has hired a private plane to deliver 2.8 million COVID-19 diagnostic tests to European countries including Italy, Spain, Belgium, Czechia, and Lithuania...
DoctorOnCall Offers Free Medical Assistance To Flood Victims
KUALA LUMPUR, Malaysia, Dec. 29, 2021 /PRNewswire/ -- Amidst Malaysia's worst flash flooding following heavy rains over the weekend that displaced tens of thousands of people, Malaysia's first and largest digital health platform, DoctorOnCall, has announced a flood relief medical assistance initiative. A team of volunteers including Doctors and Nurses were deployed in several affected areas...
Biosyngen Pte Ltd launched biological production base for commercialization of immune cell therapeutics in China
GUANGZHOU, China, Dec. 29, 2021 /PRNewswire/ -- The inauguration ceremony of Biosyngen Pte. Ltd., ("Biosyngen") joint projects and Biosyngen biological production base was held in China-Singapore Guangzhou Knowledge City (CSGKC), on December 28th , 2021. Representatives from both countries celebrated the landmark achievement Government officials from Guangzhou Huangpu...
VISTA Eye Specialist resolved to be a Changemaker and A Force for Good with B Corp Certification.
PETALING JAYA, Malaysia, Dec. 29, 2021 /PRNewswire/ -- VISTA Eye Specialist (VISTA) believes that being one of the leading eye specialists is not just about medical care. "As part of our mission statement, we believe that other than to safely help people see their best, our goal is about changing lives. It is our greatest desire to be able...
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India
GAITHERSBURG, Md. and PUNE, India, Dec. 29, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world's largest vaccine manufacturer by volume, today announced that the Drugs Controller General of India...
EOFlow and Zihipp Announce Joint Venture for Development of Innovative Solutions for Treatment of Obesity & NASH
Establishment of Joint Venture Company named SanPlena in the US Drug-device combination of EOFlow's smart wearable drug delivery platform and novel peptide derivatives developed by a team led by Prof. Sir Stephen Bloom, world-renowned researcher in the field of obesity and metabolism at Imperial College London (UK) 10-15% weight loss in 2-3 months eyed with...
2020 Global Survey from ISAPS Sees Significant Changes in Aesthetic Procedures During Pandemic
COVID-19 practice closures lead to a 10.9% decrease in surgical procedures WEST LEBANON, N.H., Dec. 28, 2021 /PRNewswire/ -- The International Society of Aesthetic Plastic Surgery (ISAPS) released the results of its annual Global Survey on Aesthetic/Cosmetic Procedures today, which showcased the impact of the COVID-19 pandemic on aesthetic plastic surgery procedures worldwide...
Akeso’s IL-17A MONOCLONAL ANTIBODY (GUMOKIMAB) COMPLETION OF PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS
HONG KONG, Dec. 28, 2021 /PRNewswire/ -- Today, Akeso, Inc. (09926.HK) announces that Gumokimab (IL-17A monoclonal antibody, AK111), an innovative drug independently developed by the Company for the treatment of active ankylosing spondylitis has been completed. Such clinical trial aims to evaluate the efficacy and safety of Gumokimab for the treatment of patients with active ankylosing spondylitis. Ankylosing spondylitis is a...
Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor’s First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology
SHANGHAI, Dec. 28, 2021 /PRNewswire/ -- On December 23, Regor Therapeutics, a clinical-stage biotech company, announced authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans for RGT-419B. RGT-419B is a new generation CDK2/4/6, small molecule inhibitor with an optimized kinase activity spectrum. It is expected to improve the safety of...
